January 18, 2010 11:52 ET


NANTES, FRANCE--(Marketwire - January 18, 2010) - VIVALIS (NYSE Euronext: VLS), a biopharmaceutical company that provides the pharmaceutical industry with innovative cell-based solutions for the manufacture of vaccines and proteins and develops drugs to treat human diseases, today annouces its schedule for the publication of financial information for 2010.

|Event                    |Date * **           |
|2009 annual revenues     |Wednesday, 27       |
|                         |January 2010        |
|2009 annual results      |Tuesday, 6 April    |
|                         |2010                |
|Presentation of 2009     |Wednesday, 7 April  |
|annual results           |2010, 5:30 p.m.     |
|2010 first-quarter       | Tuesday, 4 May 2010|
|revenues                 |                    |
|Annual General Meeting   |Wednesday, 10 June  |
|                         |2010                |
|2010 second-quarter      |Wednesday, 21 July  |
|revenues                 |2010                |
|2010 first-half results  |Tuesday, 31 August  |
|                         |2010                |
|2010 third-quarter       |Wednesday, 20       |
|revenues                 |October 2010        |
* Subject to modification.

** Press releases are published after market closes

About the EB66® line

The EB66® cell line, derived from duck embryonic stem cells, presents unique industrial and regulatory characteristics such as long-term genetic stability, immortality and cell growth to high cell densities in suspension in a serum-free medium (>20 millions cells/mL).

The BMF (Biologics Master File) for the registration of the EB66® cell line with the FDA (U.S. Food and Drug Administration) was filed on June 27, 2008.

The EB66® cell line is currently used or being tested by 75% of the major players in vaccines. VIVALIS has furthermore demonstrated that the EB66® cell line can be easily genetically modified, permitting the expression of recombinant proteins of potential interest. Moreover the glycosylation profile of monoclonal antibodies produced through EB66® cell lines is similar to the glycosylation profiles of human monoclonal antibodies with the added benefit of being distinguished by reduced fucose content. This latter characteristic is known to be associated with a higher level of antibody cytotoxic activity, particularly useful in the treatment of cancer cells.


VIVALIS (NYSE- Euronext: VLS) is a biopharmaceutical company that provides innovative cell-based solutions to the pharmaceutical industry for the manufacture of vaccines and proteins, and develops drugs for the prevention and treatment of viral diseases. VIVALIS' expertise and intellectual property are exploited in three main areas:

1. VIVALIS offers research and commercial licenses for its EB66® cell line, derived from duck stem cells, to pharmaceutical and biotechnology companies for the production of vaccines. VIVALIS receives upfront fees, milestone payments and royalties on its licensees' net sales.

2. Through the Humalex® platform, VIVALIS proposes customers solutions for the generation, development and production of human antibodies. VIVALIS receives upfront fees, milestone payments and royalties on its licensees' net sales.

3. The construction of a portfolio of proprietary products in the area of vaccines and anti-viral molecules (hepatitis C).

Based in Nantes (France), VIVALIS was founded in 1999 by the Grimaud group (1,450 employees), the second largest group worldwide in animal genetic selection. VIVALIS has established more than 30 partnerships and licenses with world leaders in this sector, including Sanofi Pasteur, GlaxoSmithKline, Novartis Vaccines, Merck, CSL Kaketsuken, Merial, Intervet, SAFC Biosciences. VIVALIS is a member of the French ATLANTIC BIOTHERAPIES bio-cluster.

|VIVALIS                  | |
|Listed on Euronext Paris | |
|– Compartment C of NYSE  | |
|Euronext                 | |
|Reuters: VLS.PA –        | |
|Bloomberg: VLS FP        | |
|Included in NYSE         | |
|Euronext’s SBF 250, CAC  | |
|Small 90 and Next Biotech| |
|indexes                  | |


Franck Grimaud, CEO



Financial communications agency

Steve Grobet / Emmanuel Huynh

Tel.: +33 (0) 1 44 71 94 91


This information is provided by HUGIN

Contact Information